SynthesisFrontiers in oncology2026
Risk of osteoporosis and fracture among patients with breast cancer: a systematic review and meta-analysis of cohort studies.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer survivors may be at increased risk of osteoporosis and fractures because of disease-related factors and treatment-induced bone loss. However, the available evidence remains inconsistent. This study aimed to evaluate the associations between breast cancer and the risks of osteoporosis and fracture through a systematic review and meta-analysis. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched from database inception to May 1, 2026. Cohort studies investigating the associations between breast cancer and the risks of osteoporosis or fracture were included. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were pooled using random-effects models. Subgroup analyses were performed according to age and treatment modality. Results: A total of 16 cohort studies were included in this meta-analysis. The pooled analysis demonstrated that breast cancer was associated with significantly increased risks of osteoporosis (HR = 1.54, 95% CI: 1.13-2.09) and fracture (HR = 1.49, 95% CI: 1.03-2.16). Age-stratified findings suggested comparable osteoporosis risks between women aged <50 years and those aged ≥50 years. In the treatment subgroup analysis, aromatase inhibitor therapy was associated with a significantly increased risk of osteoporosis (HR = 1.65, 95% CI: 1.05-2.60), whereas no significant associations were observed among tamoxifen users or patients receiving chemotherapy. Conclusion: Breast cancer is significantly associated with increased risks of both osteoporosis and fracture. Aromatase inhibitor therapy may further contribute to osteoporosis risk. These findings highlight the importance of bone health monitoring and fracture prevention strategies in breast cancer survivors. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261419796, identifier CRD420261419796.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.